There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...
Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback